title: Managing toxicities in pelvic malignancies.
abstract: Pelvic malignancies, including bladder, prostate, and gynecologic cancers, are typically treated with some form of radiation therapy. Reducing radiation-related toxicities in these patients is important for maintaining good quality of life as survival rates increase and also for directly affecting cure rates by reducing delays in radiotherapy. Amifostine (Ethyol) has been shown to reduce rectal bleeding in patients with prostate cancer treated with radiation therapy, prevent radiation-related dermatitis, and provide widespread mucosal protection without adversely affecting local or distant tumor control.
authors.affiliation: University Community Hospital, Center for Cancer Care, Tampa, FL 33613, USA. jfriedland@mail.uch.org
authors.forename: Jay
authors.initials: J
authors.lastname: Friedland
mesh_terms: D004999:Amifostine / Q000008:administration & dosage / Q000627:therapeutic use*; D003872:Dermatitis / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D009092:Mucous Membrane / Q000187:drug effects / Q000473:pathology; D010386:Pelvic Neoplasms / Q000532:radiotherapy*; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011837:Radiation-Protective Agents; D004999:Amifostine